Colorectal Cancers

MRD Testing to Guide Adjuvant Chemotherapy for Resected Colon Cancer

John Strickler, MD
MRD Surveillance for Locally Advanced Rectal Cancer

John Strickler, MD
Impact of ctDNA Testing on Survival: Can MRD Testing Make a Difference for Metastatic CRC

John Strickler, MD
Key Advances in the Management of Colorectal Cancer – The Role of Molecular Residual Disease (MRD) Assessment

Tanios S. Bekaii-Saab, MD
$Management of Chemotherapy Refractory CRC –Where the Art of Medicine Meets the Science$

Management of Chemotherapy Refractory CRC –Where the Art of Medicine Meets the Science

John Strickler, MD
Update on ctDNA in Management of Colon Cancer

John Strickler, MD
Targeting KRAS: Beyond KRAS G12C

John Strickler, MD
Blood-Based Testing to Detect Genomic Amplification: Lessons from HER2

John Strickler, MD
Targeting MTAP Loss: Preliminary Data for an Emerging Target

John Strickler, MD
Targeting KRAS G12C: Focus on Lung Cancer and GI Malignancies

Charu Aggarwal, MD, MPH; John Strickler, MD
c-Met as an Emerging Target in Advanced Colorectal Cancer

John Strickler, MD
First-Line Treatment of Metastatic Colorectal Cancer A DEEPER Understanding of Predictive Biomarkers Generates Novel

John Strickler, MD